delavirdine


Also found in: Dictionary, Thesaurus, Wikipedia.

delavirdine

 [del″ah-vir´dēn]
an antiretroviral agent, that acts as a non-nucleoside reverse transcriptase inhibitor; administered orally as the mesylate salt in treatment of human immunodeficiency virus infection.

delavirdine

/del·a·vir·dine/ (del″ah-vir´dēn) an antiretroviral, inhibiting reverse transcriptase; used as the mesylate salt in the treatment of HIV infection.

delavirdine

(dĕl′ə-vîr′dēn)
n.
An antiviral drug, C22H28N6O3S, that is a non-nucleoside reverse transcriptase inhibitor and is used in its mesylate form in combination with other drugs for the treatment of HIV infection.

delavirdine

a nonnucleoside reverse transcriptase inhibitor.
indications It is used to treat HIV-1 in combination with zidovudine or didanosine.
contraindications Known hypersensitivity to this drug or to atevirdine prohibits its use.
adverse effects Life-threatening effects are hepatotoxicity, neutropenia, leukopenia, thrombocytopenia, anemia, granulocytopenia, and nephrotoxicity. Other adverse effects include diarrhea, abdominal pain, nausea, fatigue, headache, rash, pain, myalgia, vomiting, and dyspepsia.
References in periodicals archive ?
Nevirapine is similar to delavirdine, causing a decrease of about 50% in methadone area-under-the-curve concentrations.
Selectivity testing (Table 5) demonstrated that the nelfinavir M8 metabolite elutes close to this potential internal standard, as does delavirdine, a non-nucleoside HIV reverse transcriptase inhibitor.
For example, a study of the drug delavirdine, in which 19 percent of the participants were women, showed a longer retention time in women s bodies than in men s (Women Alive, 1997).
In two trials of delavirdine taken with other inhibitors of reverse transcriptase, investigators have found that they can accurately figure the odds that a patient will maintain good health.
US FDA PREGNANCY CATEGORIES FOR CURRENTLY APPROVED ANTIRETROVIRALS Drug FDA category Abacavir C Didanosine B Emtricitabine B Lamivudine C Stavudine C Tenofovir B Zalcitabine C Zidovudine C Delavirdine C Efavi renz D Nevirapine C Amprenavir C Atazanavir B Darunavir B Fosamprenavir C Indinavir C Lopinavir + C ritonavir Nelfinavir B Ritonavir B Saquinavir B Tipranavir C Enfuvirtide B FDA categories defined as: A: Adequate and well-controlled studies of pregnant women fail to demonstrate a risk to the fetus during the first trimester of pregnancy (and no evidence exists of risk during later trimesters).
Drugs: delavirdine and nelfinavir (see Table I) Peripheral consumption * Idiopathic thrombocytopenic purpura * Diffuse intravascular coagulopathy * Thrombotic thrombocytopenic purpura Peripheral sequestration/hypersplenism * Infections * Haemophagocytosis * Cirrhosis
1995,288:201-207 (37) TABLE 3 Drugs that induce or inhibit CYP3A4 Inducers Barbiturates Glucocorticoids Carbamazepine Modafinil Dexamethasone Nevirapine Efavirenz Phenobarbital Weak/moderate Amiodarone Diltiazem inhibitors Anastrozole Fluconazole Chloramphenicol Fluoxetine Cimetidine Fluvoxamine Ciprofloxacin Metronidazole Clotrimazole Mibefradil Danazol Miconazole Delavirdine Strong inhibitors * Clarithromycin Indinavir Erythromycin Itraconazole Inducers Phenylbutazone Rifabutin Phenytoin Rifampin Pioglitazone St.
The FDA approves the NNRTI delavirdine (Rescriptor).
Some patients may be sensitive to non-nucleoside reverse transcriptase inhibitors such as nevirapine, delavirdine, and efavirenz.
This is a very active antiretroviral of the NNRTI class (non-nucleoside reverse transcriptase inhibitor -- the same class as efavirenz, nevirapine, and delavirdine, the three NNRTI drugs currently approved in the U.